Last reviewed · How we verify
Fulvestrant injection (fulvestrant-injection)
Fulvestrant binds to estrogen receptors in breast cancer cells, leading to their degradation and inhibiting tumor growth.
At a glance
| Generic name | fulvestrant-injection |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Mechanism of action
Fulvestrant works by attaching to estrogen receptors in breast cancer cells, which causes these receptors to break down. This prevents the cancer cells from growing and spreading.
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Fatigue
- Arthralgia
- Vomiting
- Hyperglycaemia
- Neutropenia
- Decreased appetite
- Rash
- Headache
- Back pain
- Constipation
Key clinical trials
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (PHASE1, PHASE2)
- Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. (PHASE3)
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors (PHASE1)
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fulvestrant injection CI brief — competitive landscape report
- Fulvestrant injection updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI